RuDo Logo
Talk to an adviser

Kotak Healthcare Fund

Pharma and Healthcare · Direct plan · Growth

₹18.74

+₹0.05 (+0.27%) today

NAV on 20 Nov 2026Near its 52-week high

This fund +33.18%NIFTY Healthcare +18.04%past 5 days

Returns

Up to a year

PeriodThis fundNIFTY HealthcareRank
1 month+11.92%+12.34%8/19
3 months+7.61%+6.15%2/18
6 months+19.09%+10.59%1/18
This year+36.70%+19.97%1/18
1 year+33.18%+18.04%1/17

Longer term

This fundNIFTY Healthcare
TotalA yearA yearRank
2 years+38.83%+17.8%+13.0%–
3 years––+20.9%–
5 years––+15.6%–
7 years––+21.2%–
10 years––+12.3%–
Since inception+87.35%+23.8%+20.7%–

₹1 lakh invested 2 years ago is ₹1.39 lakh today.

From the plan's own NAV, to 20 Nov 2026. Rank 1 is best. Past returns are no guide to the future.

RiskWorst fall -18.0% · volatility 16.3% a year

Volatility, 3 years

16.3%

NIFTY Healthcare 16.4%

Worst fall

-18.0%

Mar 2025, back by May 2026

Worst calendar year

-5.8%

2025

Up months

63%

last 3 years

Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)

Volatility

= 16.3%

In line with peers · average 16.0%

10 of 13

Yearly cost

= 1.03%

About average · average 1.10%

8 of 18

More measures ›

Sharpe ratio, 3 years

N/A

Return above the CRISIL Overnight Index per unit of volatility

Sortino ratio, 3 years

N/A

The same, counting only falls

Alpha vs NIFTY Healthcare

N/A

Yearly return beyond what its beta explains

Beta vs NIFTY Healthcare

N/A

Moves this much when the index moves 1%

Share of the index's rises

103%

In months the index rose

Share of the index's falls

86%

In months the index fell; lower is better

Over the last 3 years, from the fund's NAVs against the NIFTY Healthcare.

Where it ranksAgainst 19 pharma and healthcare funds

Category rank, year by year

In the top half of pharma and healthcare funds in 1 of 3 calendar years.

Top quarter in 1, bottom quarter in 1.

1/18

Rank in 2026 YTD

'17

N/A

'18

N/A

'19

N/A

'20

N/A

'21

N/A

'22

N/A

'23

N/A

'24

Q3

'25

Q4

'26

Q1

Each year ranks the pharma and healthcare funds by that year's return from their own Direct Growth NAV; Q1 is the top quarter. 2026 is year to date. The peer group is today's funds, so funds that closed or merged in earlier years are not counted. Past performance does not indicate future returns.

Where it ranks

among 19 pharma and healthcare funds, Direct plans

1 year

1 of 17

Top quarter

Lowest cost

8 of 18

Second quarter

Best over 3 years3 yearsCost
1HDFC Pharma and Healthcare Fund+123.0%1.04%
2SBI Healthcare Opportunities Fund+94.4%1.00%
3Mirae Asset Healthcare Fund+90.9%0.61%
4UTI Healthcare Fund+87.3%1.34%
5LIC MF Healthcare Fund+80.9%1.38%
13Kotak Healthcare Fund this fund–1.03%

Every fund in the category computed from its own NAV the same way, to 20 Nov 2026. All Pharma and Healthcare funds ›

What stands out

What it holds

36 holdings · as of Aug 2026

  1. 1Sun Pharmaceutical Industries Ltd13.96%
  2. 2Divi'S Laboratories Ltd9.25%
  3. 3Torrent Pharmaceuticals Ltd4.75%
  4. 4Molbio Diagnostics Ltd4.53%
  5. 5Max Healthcare Institute Ltd4.34%
  6. 6AMI Organics Ltd3.91%
  7. 7Cipla Ltd3.67%
  8. 8Park Medi World Ltd3.36%
  9. 9Yatharth Hospital & Trauma Care Services Ltd3.25%
  10. 10Apollo Hospitals Enterprises Ltd3.25%
Top 10: 54.3% of the fund
P/E 61.2 · Turnover 27% a yearCheck overlap with another fund ›

SIP returns of pharma and healthcare funds · All pharma and healthcare funds · Fund screener

About Kotak Healthcare Fund Direct Plan Growth Option

Kotak Healthcare Fund Direct Plan Growth Option is a Sector Specific - Pharma equity fund from Kotak Mahindra Asset Management Company Limited, launched on 4 Dec 2023. Its benchmark is the NIFTY Healthcare Index. The expense ratio is 1.03% a year. It manages ₹861 crore. The NAV was ₹18.73 on 20 Nov 2026.

Questions about Kotak Healthcare Fund

What is the NAV of Kotak Healthcare Fund Direct Growth?

The NAV of Kotak Healthcare Fund Direct Growth was ₹18.73 on 20 Nov 2026. Mutual fund NAVs are published once a day, after markets close.

What are the returns of Kotak Healthcare Fund Direct Growth?

Kotak Healthcare Fund Direct Growth returned 33.2% over 1 year, to 20 Nov 2026, worked out from its own daily NAV. It returned more than the NIFTY Healthcare Index in 2 of 4 calendar years since 2023.

What is the expense ratio of Kotak Healthcare Fund Direct Growth?

1.03% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.

Can NRIs in the UAE invest in Kotak Healthcare Fund?

NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Kotak Mahindra Mutual Fund accepts investors living in the US or Canada only on conditions, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.

How are Kotak Healthcare Fund gains taxed for NRIs?

India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.

Rolling returns shows every period, not just the latest.

Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

Investing from the UAE. NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Some fund houses restrict residents of the US and Canada. India taxes equity fund gains at 20% on units held 12 months or less and 12.5% above ₹1.25 lakh a year after that, plus cess and any surcharge, deducted when an NRI redeems. The UAE has no personal income tax and the India UAE treaty may apply, so confirm your position with a tax adviser.

Data from RuDo Wealth fund analytics, NAV as of 20 Nov 2026; benchmark as named by Kotak Mahindra Asset Management Company Limited. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. General information, not a recommendation to buy or sell this fund. Past performance does not indicate future returns.